I would be interested in hearing the response to your query, as would many others, I'm sure. Please keep us updated. While I'm not fully decided on the RS yet, I have to say that I'm not very happy with the way things have been going recently. There are too many questions that the company has failed to answer, despite the claim of transparency. For example:
1) Why did the CEO and CFO cost the company over $5 million last year?
2) What steps are going to be taken to ensure any newly authorized shares only add value to the shareholders (as opposed to compensation for the Board of Directors)? What percentage of authorized shares would be sold, and what percentage would be used as leverage?
3) What is the current plan, laid out in detail, to achieve profitability? Buying CCEL De Mexico is not a silver bullet, and I do not believe it alone will make CBAI profitable (though it will certainly help).
4) What progress towards profitability was made last year? For example, since purchasing Stellacure, what steps have been made to make it profitable? How many samples do we now have in Las Vegas? Has the rate of samples being collected each month gone up with CBAI's program to educate nurses? If so, how much, and what is the projection for this year? What was the success of the Afford a Cord program? What were the company's major expenses last year, and how can they be reduced (cutting costs is just as important as increasing revenue)? How many samples were collected in Hawaii? Are we expecting the same rate or better for the new insurance partners that were recently added?
NOTE: I do not believe the answers to any of these questions would benefit the competition. In the growing world of stem cells, I believe there is more than enough room for all companies involved, and that the growth of one company actually benefits all companies, by increasing exposure and consumer awareness. For example, in the industry I'm in, we get excited when a competing product does well, because that signals that there is consumer interest in the market we're targeting.
Market Data 
Markets 
AI
